Real-world data backs anti-IL-5 use in COPD with comorbid asthma EP News Bureau May 22, 2025 GlobalData’s latest analysis highlights the results of a retrospective study from Ghent University Hospital based on Belgian…
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:… EP News Bureau May 20, 2025 GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…
GSK’s Nucala highlights IL-5 inhibition in reducing COPD exacerbations in eosinophilic patients:… EP News Bureau May 19, 2025 In both groups, Nucala significantly lowered the rate of exacerbations requiring emergency department (ED) visits or…
